Monte Rosa Therapeutics, Inc. - Common Stock (GLUE)

Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Monte Rosa Therapeutics (GLUE) reported Q2 2025 earnings with revenue beating estimates at $23.2M and a narrower EPS loss of -$0.15. Shares dipped pre-market despite strong results, as investors await clinical progress in its molecular glue degrader pipeline.

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.

GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.